Literature DB >> 32211453

Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer.

Mozhde Askari1, Amid Yazdani1, Mohammad Yazdani2, Mohammad Hossein Izadpanahi2.   

Abstract

BACKGROUND: Urine test with the PSA result will provide a good prognosis of the prostate cancer. Therefore, considering the importance of PCA3 in this study, we aimed to compare the serum total and urinary PCA3 levels in patients with benign hyperplasia and prostate cancer.
METHODS: This cross-sectional study was performed on 90 patients referring to Noor and Hazrat-e-Ali Asghar Hospital in Isfahan from October 2017 to October 2018 for prostate biopsy. Patients were divided into two groups including benign prostate hyperplasia (BPH) and prostate cancer. Serum total and urinary PCA3 levels were measured and compared in both groups.
RESULTS: 38 patients with prostate cancer and 52 patients with BPH participated in this study. Mean age in prostate cancer group was significantly higher than BPH group (P=0.01). Also mean PCA3, and total PSA, in patients with prostate cancer was significantly higher than patients with BPH (P<0.05).
CONCLUSION: PCA3 was an important marker in patients with prostate cancer and BPH. AJCEU
Copyright © 2020.

Entities:  

Keywords:  Urine test; benign prostate hyperplasia; markers; prostate cancer

Year:  2020        PMID: 32211453      PMCID: PMC7076296     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  11 in total

1.  [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].

Authors:  D S Mikhaylenko; D V Perepechin; M V Grigoryeva; T A Zhinzhilo; N Yu Safronova; G D Efremov; A V Sivkov
Journal:  Urologiia       Date:  2015 Sep-Oct

2.  The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Authors:  Mo Shen; Wei Chen; Kaiyuan Yu; Zhanguo Chen; Wu Zhou; Xiaomei Lin; Zhiliang Weng; Chengdi Li; Xiuling Wu; Zhihua Tao
Journal:  Exp Mol Pathol       Date:  2010-10-20       Impact factor: 3.362

3.  Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.

Authors:  Cecilia Bosco; Hans Garmo; Jan Adolfsson; Pär Stattin; Lars Holmberg; Per Nilsson; Adalsteinn Gunnlaugsson; Anders Widmark; Mieke Van Hemelrijck
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-01       Impact factor: 7.038

4.  PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

Authors:  Christian G Ramos; Raul Valdevenito; Ivonne Vergara; Patricio Anabalon; Catherine Sanchez; Juan Fulla
Journal:  Urol Oncol       Date:  2012-06-09       Impact factor: 3.498

5.  Comparing urine levels of BLCA-4 nuclear matrix protein in patients with bladder cancer and non-bladder cancer.

Authors:  Ali Alavi; Mohammad-Hosein Izadpanahi; Leila Haghshenas; Romina Faridizad; Mohammad-Javad Eslami; Keyvan Ghadimi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-12-15

Review 6.  Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Authors:  Marco Auprich; Anders Bjartell; Felix K-H Chun; Alexandre de la Taille; Stephen J Freedland; Alexander Haese; Jack Schalken; Arnulf Stenzl; Bertrand Tombal; Henk van der Poel
Journal:  Eur Urol       Date:  2011-08-25       Impact factor: 20.096

Review 7.  Systematic review and meta-analysis of prostatic artery embolisation for lower urinary tract symptoms related to benign prostatic hyperplasia.

Authors:  J-S Pyo; W J Cho
Journal:  Clin Radiol       Date:  2016-11-15       Impact factor: 2.350

Review 8.  Prostate-specific antigen and other serum and urine markers in prostate cancer.

Authors:  Carsten Stephan; Bernhard Ralla; Klaus Jung
Journal:  Biochim Biophys Acta       Date:  2014-04-13

9.  Feasibility, complication and long-term follow-up of the newly nelaton based urethral dilation method, retrospective study.

Authors:  Jalil Hosseini; Morteza Fallah-Karkan; Amirhossein Rahavian; Farzin Soleimanzadeh; Hojjat Salimi; Keyvan Ghadimi; Maryam Fahim
Journal:  Am J Clin Exp Urol       Date:  2019-12-15

Review 10.  Urine microRNAs as potential noninvasive biomarkers in urologic cancers.

Authors:  Hana Mlcochova; Renata Hezova; Michal Stanik; Ondrej Slaby
Journal:  Urol Oncol       Date:  2013-09-10       Impact factor: 3.498

View more
  1 in total

Review 1.  Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.

Authors:  Ian Wang; Liankun Song; Beverly Y Wang; Arash Rezazadeh Kalebasty; Edward Uchio; Xiaolin Zi
Journal:  Am J Clin Exp Urol       Date:  2022-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.